FBIO
Fortress Biotech, Inc.
3.19
2 x 2.27
2 x 3.98
bid
ask
+
0.10
3.07%
09:51 AM
timesize
Ytd-12.98%
1y74.04%
3.09
day range
3.19
1.77
52 week range
4.53
Open3.09Prev Close3.09Low3.09High3.19Mkt Cap105.80M
Vol31.70KAvg Vol439.91KEPS3.23P/E0.99Forward P/E-0.99
Beta1.75Short Ratio4.57Inst. Own15.78%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1350-d Avg2.63200-d Avg2.981yr Est14.33

FBIO News

Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
seekingalpha.com
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?

Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortres

Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
globenewswire.com
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference

SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Jou

Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
globenewswire.com
Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference

MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innov

benzinga.com
Fortress Biotech Q1 EPS $2.82 Beats $(0.22) Estimate, Sales $16.038M Miss $16.338M Estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $2.82 per share which beat the analyst

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Th

Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highli

Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 mill

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
globenewswire.com
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

Company to host conference call to discuss financial results and provide a corporate update on May 1

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
globenewswire.com
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innov

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
globenewswire.com
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 millio

benzinga.com
Fortress Biotech Q4 EPS $(0.30) Beats $(0.42) Estimate, Sales $16.079M Miss $21.018M Estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.30) per share which beat the analyst

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
globenewswire.com
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Th

benzinga.com
Fortress Biotech And Cyprium Therapeutics Announce The Closing Of The Sale Of Cyprium's Rare Pediatr

Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium

Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
globenewswire.com
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Re

MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
globenewswire.com
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™  generated

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
globenewswire.com
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Company to host conference call to discuss financial results and provide a corporate update on March

Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving Average   – What’s Next?
defenseworld.net
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving Average – What’s Ne

Fortress Biotech, Inc. (NASDAQ: FBIO - Get Free Report)'s share price crossed above its 200-day movi

benzinga.com
HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $17 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Fortress Biotech (NASDAQ:FBIO) with a

UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
globenewswire.com
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediat

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its

Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
globenewswire.com
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Dise

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
globenewswire.com
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment o

ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved

Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap
seekingalpha.com
Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap

Fortress Biotech is essentially a holding company biotech with a dermatology revenue base (Journey M

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average   – Here’s What Happened
defenseworld.net
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average – Here’s What Happened

Fortress Biotech, Inc. (NASDAQ: FBIO - Get Free Report) shares crossed above its two hundred day mov

Fortress Biotech (NASDAQ:FBIO) Shares Pass Above 200-Day Moving Average   – What’s Next?
defenseworld.net
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above 200-Day Moving Average – What’s Next?

Fortress Biotech, Inc. (NASDAQ: FBIO - Get Free Report) shares crossed above its 200-day moving aver

benzinga.com
Fortress Biotech Announces FDA Approves Its ZYCUBO To Treat Menkes Disease In Pediatric Patients

Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cypriu

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
globenewswire.com
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate)

Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred fr

benzinga.com
Fortress Biotech Q3 EPS $0.11 Beats $(0.42) Estimate, Sales $17.631M Miss $21.018M Estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $0.11 per share which beat the analyst

benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
benzinga.com
Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Movi

benzinga.com
Fortress Biotech And Cyprium Therapeutics Announce FDA Issues CRL Relating To NDA For CUTX-101, Inte

Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium

benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why Ryvyl Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Ryvyl Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket

Why Docusign Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Docusign Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com
HC Wainwright & Co. Maintains Buy on Fortress Biotech, Lowers Price Target to $17

HC Wainwright & Co. analyst Joseph Pantginis maintains Fortress Biotech (NASDAQ:FBIO) with a

benzinga.com
CORRECTION: Fortress Biotech Q2 Adj. EPS $(0.46) Misses $(0.36) Estimate, Sales $16.413M Beat $14.53

Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.46) per share which missed the analy

benzinga.com
Around $10M Bet On This Tech & Telecom Stock? Check Out These 3 Stocks Insiders Are Buying

benzinga.com
Greenbrier, Fortress Biotech And 3 Stocks To Watch Heading Into Monday

benzinga.com
Why Fisker Shares Are Trading Higher By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day S

Shares of Fisker Inc. (NYSE: FSR) rose sharply during Friday’s session after the company provided a

benzinga.com
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's

Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the comp

benzinga.com
Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid

Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported thi

benzinga.com
Why Direct Digital Shares Are Trading Higher By Around 33%; Here Are 20 Stocks Moving Premarket

Shares of Direct Digital Holdings, Inc. (NASDAQ: DRCT) rose sharply in pre-market trading after the

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  Tuesday saw 132 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  On Tuesday, 99 stocks hit new 52-week lows.

benzinga.com
Pancreatic Cancer Action Network Urges Advocates From All 50 States To Call On Congress To Increase

Federal Funding Increases Fuel Research Progress and Help Improve Patient OutcomesLOS ANGELES, June

benzinga.com
Earnings Scheduled For May 26, 2023

Companies Reporting Before The Bell • LightInTheBox Holding (NYSE:LITB) is estimated to report earn

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  On Thursday, 116 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  On Wednesday, 258 companies hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  OnFriday, 143 stocks hit new 52-week lows.

benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session